T he use of somatic interventions to control or treat mental symptoms dates back to ancient times. 1, 2 During 1917 to 1937, 4 methods for producing physiological shock were discovered, tested, and used in psychiatric practice for treating psychosis: fever, insulin-induced coma, medication-induced convulsions, and electrically induced convulsions. In 1937, Cerletti and Bini 3 applied transcranial electroconvulsive shock therapy to induce seizures safely and reliably. It was received with great enthusiasm, given the remarkable therapeutic effects (in patients who now would most likely be classified as psychotically depressed) and the technical ease of administration, compared with insulin or metrazol shock. Since then, electroconvulsive therapy (ECT) has become the method of choice for convulsive therapy. 4 It is currently reserved for treatment-resistant depression or special patient populations, such as the elderly. More than 60 years of experience has significantly improved this technique and made it safer to administer. However, it is associated with cognitive side effects and a high relapse rate. It is noteworthy that unlike other contemporary somatic interventions, such as transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS), the Food and Drug Administration (FDA) never approved ECT for clinical use as such regulations came into effect much later.
TMS, the subject of 2 expert reviews in this issue, is another form of somatic therapy and refers to a technique by which electrodeless stimulation of the cells is produced by a rapid oscillation in electrical and then magnetic energy. If activated over the skull, it allows access to a network of anatomically and functionally related brain regions through local noninvasive stimulation of the cortex. It influences deeper brain structures through neuronal conduction. TMS in itself is not a new idea. In 1896, the French engineer Arsenne d'Arsonval applied TMS over the retina and induced phosphenes. Interestingly, even then, and in a communication of the French Society, he also noted "other psychological effects that should be studied further." 5, p 450-451 In 1910, Pollacsek and Beer filed a patent in Vienna to use magnetic stimulation for the treatment of depression. However, it was not until the 1990s that the technology became sufficiently developed to allow induced electromagnetic fields that caused cortical neuron depolarization. 6 With a growing knowledge of the distributed neuronal networks involved in various neuropsychiatric phenomena, work with TMS has quickly expanded from early investigations of motor electrophysiology to using it as a tool to modulate (and possibly regulate) dysfunctional brain regions. TMS applications are designed to be subconvulsive in nature, hence they differ substantially from ECT and do not require general anesthesia. TMS also does not necessitate any implantable stimulating devices such as VNS or DBS and so is relatively easy to administer in alert and awake subjects under medical supervision. In this issue, Dr Z Jeff Daskalakis 7 and Dr Paul B Fitzgerald 8 have each summarized the substantial clinical investigations of TMS that took place during the last decade in 2 psychiatric disorders: depression, largely focused on unipolar major depressive disorder, and schizophrenia.
There is mounting evidence that prefrontal TMS, repeated over several weeks, has a clinically significant acute antidepressant effect. However, the effect sizes demonstrated were variable and not always positive. Few studies explored long-term maintenance regimens. Anecdotal reports suggest a specific decrease in suicidal ideations. Recent data imply that higher numbers of stimuli per session and longer treatment courses are more effective. A systematic exploration of stimulation parameters and delivery schedule is still lacking. The unique neuromodulation properties of intermittent stimulation (as opposed to continuous mode of deliver as in DBS for Parkinson disease or tremor) are also not well explored. The real challenge will be to integrate these clinical therapeutic benefits to an underlying mechanism of neuronal plasticity and stress desensitization.
The experience with TMS and schizophrenia is less substantial than with depression but equally exciting. Here researchers have focused primarily on treatment of symptom clusters rather than the overall psychiatric state. The major effort has involved quenching auditory hallucinations with temporal lobe stimulation at low frequency. Other studies have investigated prefrontal treatment of psychosis or negative symptoms.
Two common methodology limitations have surfaced with both clinical applications. Knowing that the probabilistic 5-cm rule for targeting the prefrontal cortex is roughly associated with a third of the patient population stimulated over the premotor area may explain the limited clinical efficacy observed in some studies. A critical development in the optimization of TMS delivery was the need to specifically target the prefrontal cortex and adjust stimulation intensity to insure adequate stimulation. 9 Similarly, variable coil positioning has also hindered temporal lobe stimulation. In addition, researchers used several approaches to administer sham TMS. One method is to use a coil that mimics the popping sound of the discharge without induction of magnetic fields. Another more widely adopted technique is to hold the coil obliquely to the scalp, which mimics the sensation of actual TMS, with contraction of scalp muscles and loud noise. Different sham angles were shown to generate a range of intracerebral current. 10 In most sham-controlled trials discussed, the administration of sham TMS was performed by an unmasked clinician who could conceivably influence the outcome. Those shortcomings of current TMS research are currently addressed with more sophisticated sham coils and elaborate study designs that approximate the double-blind conditions expected in clinical trials.
In a relatively short period, TMS has made substantial strides. The American Medical Association has approved a special Current Procedural Terminology code for tracking TMS applications and an effort is under way to get FDA approval for treating depression. Because it increases the risk of seizures, it is unlikely that TMS machines will be used without medical supervision in the way that light boxes are now used. However, more research is still needed before TMS can be seen as an integral part of the clinical armamentarium against depression or schizophrenia. Let the work continue! Funding and Support Dr Nahas received a research grant from the National Institute of Mental Health, the National Alliance of Research on Schizophrenia and Depression, Hope for Depression Research Foundation, Neuronetics Inc, Cyberonics Inc, Medtronic Inc, and Integra. Dr Nahas is also a consultant for Neuronetics Inc, Cyberonics Inc, and Neuropace, and in the speaker bureau for Cyberonics Inc.
